Revenue and Profit - Revenue for Q1 2022 reached RMB 3,479,027,465.92, an increase of 3.86% compared to RMB 3,349,814,145.87 in the same period last year[2] - Net profit attributable to shareholders was RMB 553,293,797.77, reflecting a growth of 6.47% from RMB 519,651,078.57 year-on-year[2] - Net profit excluding non-recurring items increased by 15.61% to RMB 561,046,433.69 from RMB 485,302,200.16 in the previous year[2] - The company achieved operating revenue of RMB 3,479.03 million, a year-on-year increase of 3.86%[7] - Total profit for the current period was RMB 723,790,862.48, an increase from RMB 703,848,522.76 in the previous period, representing a growth of 2.68%[16] Earnings Per Share - The basic earnings per share for the quarter was RMB 0.59, up 5.36% from RMB 0.56 in the same period last year[2] - The diluted earnings per share increased by 7.27% to RMB 0.59 from RMB 0.55 year-on-year[2] - Basic earnings per share rose to 0.59, up from 0.56 in the previous period, reflecting a growth of 5.36%[17] Cash Flow - Operating cash flow net amount rose significantly by 38.03% to RMB 710,308,938.96 compared to RMB 514,620,182.77 in the same quarter last year[2] - The net cash flow from operating activities was RMB 710,308,938.96, representing a 38.03% increase compared to the previous year[8] - Cash inflow from financing activities totaled approximately ¥1.70 billion, an increase from ¥1.28 billion in the previous period, reflecting a growth of about 33%[19] - Net cash flow from financing activities was approximately ¥353.34 million, a turnaround from a negative cash flow of ¥82.49 million in the previous period[19] - The net increase in cash and cash equivalents was approximately ¥835.52 million, compared to ¥237.35 million in the previous period, representing an increase of about 252%[19] Assets and Liabilities - Total assets at the end of the reporting period were RMB 23,729,888,204.20, a 6.07% increase from RMB 22,371,915,590.82 at the end of the previous year[2] - Total current assets increased to RMB 15,807,296,634.71 from RMB 14,673,096,594.67, representing an increase of approximately 7.7%[14] - Total liabilities increased to RMB 8,799,314,102.16 from RMB 8,060,890,797.20, reflecting a growth of approximately 9.2%[15] - Short-term borrowings decreased by 31.19% to RMB 1,405,807,901.10, primarily due to repayments by subsidiaries[6] - Long-term borrowings increased significantly to RMB 1,626,661,809.48 from RMB 636,780,252.78, indicating a rise of approximately 155.5%[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 57,995, including 57,970 A-share shareholders[9] - The top shareholder, Hong Kong Central Clearing Limited, holds 312,934,017 shares, representing 33.35% of the total shares[10] - Health元药业集团股份有限公司 is the second-largest shareholder with 221,376,789 shares, accounting for 23.59%[10] Other Financial Metrics - The company reported a significant increase in right-of-use assets by 52.95% due to new lease agreements signed during the period[6] - Research and development expenses increased to RMB 288,330,797.66, a rise of 24.5% from RMB 231,485,371.64 in the previous period[16] - The company’s financial expenses increased, with interest expenses rising to RMB 23,448,658.85 from RMB 14,068,040.27, indicating a rise of 66.5%[16] - The company reported a decrease in other comprehensive income, with a net amount of RMB -14,442,932.04 compared to RMB -123,910,341.14 in the previous period, showing improvement[17] - The company’s investment income from joint ventures and associates improved significantly to RMB 15,078,700.65, compared to a loss of RMB -3,506,817.44 in the previous period[16]
丽珠医药(01513) - 2022 Q1 - 季度财报